Fiera Capital Corp Reduces Position in argenx SE (NASDAQ:ARGX)

Fiera Capital Corp trimmed its position in argenx SE (NASDAQ:ARGX) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 155,260 shares of the company’s stock after selling 3,093 shares during the quarter. Fiera Capital Corp’s holdings in argenx were worth $95,485,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARGX. Advisors Preferred LLC purchased a new position in argenx during the 4th quarter valued at about $73,000. Cromwell Holdings LLC increased its stake in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares during the period. GAMMA Investing LLC raised its holdings in shares of argenx by 44.8% during the fourth quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock valued at $155,000 after acquiring an additional 78 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares in the last quarter. Finally, Fulton Bank N.A. purchased a new stake in argenx in the fourth quarter worth $226,000. 60.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on ARGX. Wells Fargo & Company boosted their price objective on shares of argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. boosted their price target on shares of argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Piper Sandler upped their target price on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Finally, Wolfe Research raised argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price for the company in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and an average price target of $658.39.

argenx Price Performance

Shares of argenx stock opened at $649.09 on Thursday. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21. The firm’s 50-day moving average is $638.76 and its 200 day moving average is $580.34. The stock has a market cap of $39.44 billion, a price-to-earnings ratio of -737.60 and a beta of 0.58.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.